Search - tctmd.com

Displaying 1 - 20 of 105

Sort: Relevancy | Date

News Conference News TCT 2023

CLASP IID at 1 Year: Good Results With Both Pascal, MitraClip for Mitral TEER

Todd Neale

October 26, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

News Daily News

Abbott to Stop Making Trifecta Surgical Aortic Valves

Michael O'Riordan

July 31, 2023

News Conference News EuroPCR 2023

Five-Year PORTICO IDE Data Reassure on Outcomes, Hemodynamics

Michael O'Riordan

May 17, 2023

News Conference News THT 2023

TEER or VAD/Transplant in the Advanced HF Patient With MR?

Shelley Wood

March 20, 2023

News Conference News CRT 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Yael L. Maxwell

March 03, 2023

News Daily News

FDA Alert: Possible Early Deterioration of Abbott Trifecta SAVR Valves

Todd Neale

February 27, 2023

Presentation Miami Valves 2023

Case 2: Surgical Aortic Valve Deterioration Treatment With VIV

Presenter: Ricardo Allende

February 03, 2023

News Daily News

Top Structural Heart News of 2022

L.A. McKeown

January 06, 2023

News Daily News

Aortic Valve Disease Particularly Challenging to Manage Before Age 65: Review

Todd Neale

December 28, 2022

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Conference News TCT 2022

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Michael O'Riordan

September 18, 2022

News Conference News TVT 2022

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

Michael O'Riordan

June 10, 2022

News Conference News TVT 2022

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

Michael O'Riordan

June 09, 2022

Presentation TVT 2022

POINT: The Interaction Between Echo Hemodynamics and Structural Aortic Valve Deterioration

Presenter: Michael J. Reardon

June 09, 2022

Presentation TVT 2022

Evidence of Structural Valve Deterioration After TAVI: Recent Echo Findings

Presenter: Michael J. Reardon

June 08, 2022

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

News Conference News EuroPCR 2022

Better Durability With Self-Expanding TAVI? Clues From UK TAVI

Shelley Wood

May 18, 2022

News Conference News EuroPCR 2022

Changes in Cardiac Damage After AVR Tied to 2-Year Outcomes

Caitlin E. Cox

May 17, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

Advertisement

CLASP IID at 1 Year: Good Results With Both Pascal, MitraClip for Mitral TEER

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Abbott to Stop Making Trifecta Surgical Aortic Valves

Five-Year PORTICO IDE Data Reassure on Outcomes, Hemodynamics

TEER or VAD/Transplant in the Advanced HF Patient With MR?

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

FDA Alert: Possible Early Deterioration of Abbott Trifecta SAVR Valves

Case 2: Surgical Aortic Valve Deterioration Treatment With VIV

Top Structural Heart News of 2022

Aortic Valve Disease Particularly Challenging to Manage Before Age 65: Review

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

As Time Goes By, Post-TAVI Thrombus Becomes More OAC Resistant

Surgical Explant or Redo for TAVI Failures? Some Registry Insights

Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests

POINT: The Interaction Between Echo Hemodynamics and Structural Aortic Valve Deterioration

Evidence of Structural Valve Deterioration After TAVI: Recent Echo Findings

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Better Durability With Self-Expanding TAVI? Clues From UK TAVI

Changes in Cardiac Damage After AVR Tied to 2-Year Outcomes

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content